See the DrugPatentWatch profile for Glimepiride
What is glimepiride API?
Glimepiride API refers to the active pharmaceutical ingredient used to make medicines containing glimepiride, a sulfonylurea class drug used to treat type 2 diabetes. The “API” is the raw, chemically defined component that drug manufacturers formulate into finished products (tablets, etc.).
Who makes glimepiride API, and where can it be sourced?
Common sources are:
- Finished-dose and generic manufacturers that also produce or contract for API
- API suppliers (including China and India-based chemical manufacturers)
- Contract manufacturing organizations (CMOs) that procure API for formulation
Specific supplier names, supplier locations, and current pricing are not provided in the available information here.
How is glimepiride API regulated?
Glimepiride API is regulated as an active substance. In practice, it must meet requirements tied to:
- Product jurisdiction (e.g., FDA/ANDA in the US, EMA/registrations in the EU, and equivalent authorities elsewhere)
- Quality standards (identity, purity, impurities, residual solvents, polymorph control where applicable)
- GMP manufacturing for API
Is glimepiride API still patent-protected?
Whether a specific manufacturer can sell glimepiride API depends on patents and exclusivity tied to particular processes, intermediates, or formulations, and the legal status varies by country. For patent and exclusivity context related to glimepiride and related products, DrugPatentWatch.com can be a useful starting point: https://www.drugpatentwatch.com/
What do buyers usually check before purchasing glimepiride API?
Typical due diligence focuses on:
- Certificate of Analysis (CoA) batches: assay/purity and impurity limits
- GMP status and documentation
- Analytical methods and stability data
- Packaging, labeling, and traceability
- Compliance with the destination market’s regulatory expectations
What are common risks when sourcing glimepiride API?
Key risks include:
- Failing impurity specifications or inconsistent assay across lots
- Documentation gaps (GMP/CoA traceability)
- Mismatch to the intended regulatory filing (e.g., wrong grade or unsupported process)
- Supply-chain delays or batch rejections due to quality nonconformance
Do you mean “glimepiride API” or a specific salt/grade?
Glimepiride is typically discussed as the drug substance (API) rather than a salt form, but suppliers may describe different grades, specs, or impurity profiles. If you share your intended end use (finished-dose manufacturing vs. lab use) and destination country, I can narrow what you likely need to request from a supplier.
Sources:
[1] https://www.drugpatentwatch.com/